Multidisciplinary Care Program to Secure mEdication Therapy for hematoLOgy Patients Receiving Injectable Anticancer Drugs

Study Overview
=================
Brief Summary
-----------------
Several experiences of multidisciplinary care pathways associating oncologists, pharmacists and nurses have been reported for cancer patients, with positive results on medication management safety, reduction of Drug-Related Problems (DRPs), and re-hospitalizations. This study aims to evaluate the impact of a multidisciplinary city-hospital follow-up program on medication management safety in haematological oncology patients receiving intravenous chemotherapy in onco-haematology. Additional aspects will be evaluated, such as the impact of the follow-up on the city-hospital link, satisfaction of patients and professionals involved in the follow-up and the use of telecare

Official Title
-----------------
Multidisciplinary Care Program to Secure mEdication Therapy for hematoLOgy Patients Receiving Injectable Anticancer Drugs

Conditions
-----------------
Chemotherapy Effect, G-CHOP Chemotherapy, R-CHOP Chemotherapy

Intervention / Treatment
-----------------
* Other: Assessment of patient satisfaction regarding tele-consultation
* Other: Literacy questionnaire
* Other: Collection of socio-demographic characteristics
* Other: Assessment of patient knowledge on chemotherapy side effects and support medications
* Other: Assessment of patient satisfaction on pharmaceutical follow-up


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients aged 18 years or older With hematological malignancy at any stage Initiating R-CHOP or G-CHOP chemotherapy Who do not object to participation in the study and use of collected data Exclusion Criteria: Patients already enrolled in a clinical trial evaluating any drug product Patients living in an institution Patients protected by law Adults subject to a legal protection measure (curatorship, guardianship) (article L1121-8 of the CSP) Persons deprived of their liberty by a judicial or administrative decision, persons under psychiatric care and persons admitted to a health or social establishment (article L1121-6 of the CSP)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| R-CHOP or G-CHOP chemotherapy<br>Patients with hematological malignancies receiving R-CHOP or G-CHOP chemotherapy | Other: Assessment of patient satisfaction regarding tele-consultation<br>* Questionnaire completed following the teleconsultation, if applicable.<br>Other: Literacy questionnaire<br>* Questionnaire completed during hospitalization for the first chemotherapy cycle<br>Other: Collection of socio-demographic characteristics<br>* Questionnaire completed during patient hospitalization for the first chemotherapy cycle<br>Other: Assessment of patient knowledge on chemotherapy side effects and support medications<br>* Questionnaire completed during patient hospitalization for the first, second and sixth cycle of chemotherapy<br>Other: Assessment of patient satisfaction on pharmaceutical follow-up<br>* Questionnaire completed during patient hospitalization for the sixth chemotherapy cycle<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of the clinical impact of pharmacist interventions at first cycle of chemotherapy, according to the CLEO© scale. | Each pharmacist intervention performed during patient follow-up will be rated according to its expected level of clinic impact (major, moderate, minor, null) | 6 months after inclusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Haematology, Pharmaceutical Care